| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1032973741 |
| P356 | DOI | 10.1038/MP.2011.165 |
| P932 | PMC publication ID | 3317062 |
| P698 | PubMed publication ID | 22143005 |
| P5875 | ResearchGate publication ID | 51854125 |
| P2093 | author name string | D A Rossignol | |
| R E Frye | |||
| P2860 | cites work | Effect of pioglitazone treatment on behavioral symptoms in autistic children | Q21245241 |
| Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results | Q21254631 | ||
| Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results | Q21254632 | ||
| Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial | Q21260340 | ||
| Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report | Q22241500 | ||
| Genetics evaluation for the etiologic diagnosis of autism spectrum disorders | Q22242734 | ||
| Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley | Q24569536 | ||
| Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides | Q24602033 | ||
| Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis | Q24630557 | ||
| From inflammation to sickness and depression: when the immune system subjugates the brain | Q24633527 | ||
| Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children | Q24676300 | ||
| Microglia and neuroinflammation: a pathological perspective | Q24799838 | ||
| Prenatal lead exposure, delta-aminolevulinic acid, and schizophrenia | Q24811775 | ||
| The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study | Q27496706 | ||
| Oxidative stress in hypertension | Q28217587 | ||
| Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study | Q28219023 | ||
| A preliminary trial of ascorbic acid as supplemental therapy for autism | Q28257201 | ||
| Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress | Q28257571 | ||
| Oxidative stress in psychiatric disorders: evidence base and therapeutic implications | Q28265319 | ||
| Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006 | Q28268208 | ||
| Developmental neurotoxicity of industrial chemicals | Q28279457 | ||
| Autism spectrum disorders in relation to distribution of hazardous air pollutants in the san francisco bay area | Q28391198 | ||
| Response of arsenic-induced oxidative stress, DNA damage, and metal imbalance to combined administration of DMSA and monoisoamyl-DMSA during chronic arsenic poisoning in rats | Q28564453 | ||
| Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 | ||
| ortho-substituted PCB95 alters intracellular calcium signaling and causes cellular acidification in PC12 cells by an immunophilin-dependent mechanism | Q32034830 | ||
| Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function | Q33273613 | ||
| Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control | Q33639446 | ||
| Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients | Q33751063 | ||
| Mercury induces inflammatory mediator release from human mast cells | Q33774385 | ||
| Role of oxidative stress in cardiovascular diseases | Q33953686 | ||
| Immunity, neuroglia and neuroinflammation in autism | Q33992778 | ||
| A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study | Q34009133 | ||
| Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children an | Q34010535 | ||
| Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report | Q60417993 | ||
| Ultrastructural and biochemical changes in renal mitochondria during chronic oral methyl mercury exposure: the relationship to renal function | Q67712269 | ||
| Effects of pesticides on isolated rat hepatocytes, mitochondria, and microsomes II | Q72157994 | ||
| Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats | Q73182888 | ||
| Induction of apoptosis in human T-cells by methyl mercury: temporal relationship between mitochondrial dysfunction and loss of reductive reserve | Q77754442 | ||
| Oxidative stress in autism | Q83965328 | ||
| Toxicity biomarkers in autism spectrum disorder: a blinded study of urinary porphyrins | Q84564595 | ||
| Mercury and nickel allergy: risk factors in fatigue and autoimmunity | Q34084431 | ||
| Immunological treatments for autism | Q34094304 | ||
| Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia | Q34137363 | ||
| Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome | Q34348399 | ||
| Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution | Q34363063 | ||
| Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. | Q34372384 | ||
| Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study | Q34413137 | ||
| Proximity to point sources of environmental mercury release as a predictor of autism prevalence | Q34589563 | ||
| Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. | Q34618405 | ||
| Mitochondrial disease: a practical approach for primary care physicians. | Q34721044 | ||
| Autism spectrum disorders: concurrent clinical disorders | Q34721379 | ||
| Psychiatric disorders among Egyptian pesticide applicators and formulators. | Q34743069 | ||
| Biomarkers of environmental toxicity and susceptibility in autism | Q34837538 | ||
| Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism | Q34895200 | ||
| The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders | Q34961345 | ||
| Neuroinflammation in Alzheimer's disease and prion disease. | Q34963776 | ||
| Mitochondrial involvement in psychiatric disorders | Q34994220 | ||
| Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene | Q35015897 | ||
| Diabetes, oxidative stress, and antioxidants: a review | Q35077717 | ||
| Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains | Q35153945 | ||
| Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders | Q35232104 | ||
| Neurodegenerative diseases and oxidative stress | Q35636137 | ||
| Organic mercury compounds and autoimmunity | Q36180065 | ||
| Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism | Q37029453 | ||
| Oxidative stress markers in bipolar disorder: a meta-analysis | Q37186196 | ||
| Nitrative and oxidative stress in toxicology and disease | Q37402818 | ||
| Elevated immune response in the brain of autistic patients | Q37405256 | ||
| Mechanistic biomarkers for autism treatment | Q37556922 | ||
| Improving the prediction of response to therapy in autism | Q37774095 | ||
| The role of mitochondrial dysfunction in psychiatric disease | Q37785512 | ||
| Mitochondrial DNA (mtDNA) and schizophrenia | Q37803459 | ||
| Practical guidelines for evaluating lead exposure in children with mental health conditions: molecular effects and clinical implications | Q37835625 | ||
| Metabolic biomarkers related to energy metabolism in Saudi autistic children. | Q39986451 | ||
| Aluminum-induced mitochondrial dysfunction leads to lipid accumulation in human hepatocytes: a link to obesity. | Q40086768 | ||
| Chemicals in diesel exhaust particles generate reactive oxygen radicals and induce apoptosis in macrophages. | Q40918316 | ||
| Pentoxifylline: brief review and rationale for its possible use in the treatment of autism | Q41446639 | ||
| Toxic and essential metal interactions | Q41548484 | ||
| Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism | Q42276076 | ||
| Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone | Q42551219 | ||
| Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism | Q42673710 | ||
| Neuroinflammation in schizophrenia-related psychosis: a PET study. | Q43259552 | ||
| Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. | Q43272958 | ||
| Hepatocyte lysis induced by environmental metal toxins may involve apoptotic death signals initiated by mitochondrial injury | Q43838528 | ||
| Antioxidant enzyme activities and oxidative stress in affective disorders | Q44838705 | ||
| Lead induced oxidative stress and its recovery following co-administration of melatonin or N-acetylcysteine during chelation with succimer in male rats. | Q45157215 | ||
| Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics | Q45175335 | ||
| Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children | Q46078486 | ||
| Oxidative stress in neurotoxic effects of methylmercury poisoning. | Q46176787 | ||
| The recovery of a child with autism spectrum disorder through biomedical interventions. | Q46222105 | ||
| A prospective study of transsulfuration biomarkers in autistic disorders | Q46494129 | ||
| A prospective study of mercury toxicity biomarkers in autistic spectrum disorders | Q46988646 | ||
| Mitochondrial DNA deletion mutations in patients with neuropsychiatric symptoms | Q48942369 | ||
| Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders | Q50302140 | ||
| Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome | Q50312944 | ||
| Treatment of children with autism with intravenous immunoglobulin | Q50313961 | ||
| Case study: corticosteroid treatment of language regression in pervasive developmental disorder. | Q52207067 | ||
| Neuroinflammation in Alzheimer's disease and major depression. | Q53409265 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hazardous substances | Q757138 |
| mitochondrial disease | Q935710 | ||
| autism spectrum disorder | Q1436063 | ||
| pervasive developmental disorder | Q6691991 | ||
| immune disorder | Q3843811 | ||
| publishing | Q3972943 | ||
| autism | Q38404 | ||
| research trend | Q60617927 | ||
| physiological phenomenon | Q66615932 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 389-401 | |
| P577 | publication date | 2011-12-06 | |
| 2012-04-01 | |||
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures | |
| P478 | volume | 17 |
| Q50301146 | A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder. |
| Q35218671 | A cleanroom sleeping environment's impact on markers of oxidative stress, immune dysregulation, and behavior in children with autism spectrum disorders. |
| Q36256859 | A review of gluten- and casein-free diets for treatment of autism: 2005-2015 |
| Q34392818 | A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel |
| Q37690669 | A role for metabolism in Rett syndrome pathogenesis: New clinical findings and potential treatment targets |
| Q62111589 | A systematic review of gut-immune-brain mechanisms in Autism Spectrum Disorder |
| Q26796243 | Activity dependent CAM cleavage and neurotransmission |
| Q92624736 | An integrated transcriptomic analysis of autism spectrum disorder |
| Q30979052 | An ontology for Autism Spectrum Disorder (ASD) to infer ASD phenotypes from Autism Diagnostic Interview-Revised data |
| Q59263464 | Analysis of amino acids in autism spectrum disorders |
| Q28816988 | Antibiotics May Trigger Mitochondrial Dysfunction Inducing Psychiatric Disorders |
| Q92565600 | Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis |
| Q26746354 | Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders |
| Q34344196 | Autism and dietary therapy: case report and review of the literature |
| Q60913748 | Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in amniotic fluid: a case-control study |
| Q42694581 | Autistic Siblings with Novel Mutations in Two Different Genes: Insight for Genetic Workups of Autistic Siblings and Connection to Mitochondrial Dysfunction |
| Q90428568 | Behaviorally associated changes in neuroconnectivity following autologous umbilical cord blood infusion in young children with autism spectrum disorder |
| Q93197498 | Berberine Ameliorates Prenatal Dihydrotestosterone Exposure-Induced Autism-Like Behavior by Suppression of Androgen Receptor |
| Q91522768 | Biomarker Exploration in Human Peripheral Blood Mononuclear Cells for Monitoring Sulforaphane Treatment Responses in Autism Spectrum Disorder |
| Q34519794 | Blocking and Binding Folate Receptor Alpha Autoantibodies Identify Novel Autism Spectrum Disorder Subgroups |
| Q38686745 | Blood Mercury, Arsenic, Cadmium, and Lead in Children with Autism Spectrum Disorder |
| Q26802187 | Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin |
| Q47640046 | Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism. |
| Q57456677 | Cathepsin B inhibition ameliorates leukocyte-endothelial adhesion in the BTBR mouse model of autism |
| Q34572031 | Cerebellar oxidative DNA damage and altered DNA methylation in the BTBR T+tf/J mouse model of autism and similarities with human post mortem cerebellum |
| Q46600437 | Changes in adipokine levels in autism spectrum disorders. |
| Q57922552 | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
| Q38215751 | Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder |
| Q36232865 | Comparative two-dimensional polyacrylamide gel electrophoresis of the salivary proteome of children with autism spectrum disorder. |
| Q50297309 | Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials |
| Q36300044 | Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia |
| Q26830626 | Consensus paper: pathological role of the cerebellum in autism |
| Q28680718 | Current progress and challenges in the search for autism biomarkers |
| Q42706212 | Decreased glutathione and elevated hair mercury levels are associated with nutritional deficiency-based autism in Oman |
| Q47318078 | Decreased pyramidal neuron size in Brodmann areas 44 and 45 in patients with autism |
| Q38122448 | Developing new pharmacotherapies for autism. |
| Q57800214 | Developmental protein kinase C hyper-activation results in microcephaly and behavioral abnormalities in zebrafish |
| Q54958844 | Dietary Considerations in Autism Spectrum Disorders: The Potential Role of Protein Digestion and Microbial Putrefaction in the Gut-Brain Axis. |
| Q89477432 | Dietary Phytochemicals as Neurotherapeutics for Autism Spectrum Disorder: Plausible Mechanism and Evidence |
| Q37422634 | Dietary intake and plasma levels of choline and betaine in children with autism spectrum disorders |
| Q48683161 | Does Correction of Strabismus Improve Quality of Life in Children with Autism Spectrum Disorder: Results of a Parent Survey by Ophthalmologists |
| Q38649157 | Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders? |
| Q28066841 | Dysregulated mitochondrial and chloroplast bioenergetics from a translational medical perspective (Review) |
| Q97418099 | Early life metal exposure dysregulates cellular bioenergetics in children with regressive autism spectrum disorder |
| Q37261281 | Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status |
| Q37646052 | Elevated Urinary Glyphosate and Clostridia Metabolites With Altered Dopamine Metabolism in Triplets With Autistic Spectrum Disorder or Suspected Seizure Disorder: A Case Study |
| Q37537023 | Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. |
| Q89640454 | Emerging biomarkers in autism spectrum disorder: a systematic review |
| Q28542649 | Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells--possible relevance to autism spectrum disorders |
| Q30404383 | Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders |
| Q33824115 | Environmental factors associated with autism spectrum disorder: a scoping review for the years 2003-2013. |
| Q28397071 | Environmental toxicants and autism spectrum disorders: a systematic review |
| Q38681930 | Epigenetics of Autism Spectrum Disorder |
| Q22251432 | Etiologies underlying sex differences in Autism Spectrum Disorders |
| Q22241227 | Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism |
| Q36901254 | Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems |
| Q39720986 | Expression and oxidative modifications of plasma proteins in autism spectrum disorders: Interplay between inflammatory response and lipid peroxidation |
| Q36766675 | Focal brain inflammation and autism |
| Q38645047 | Folate metabolism abnormalities in autism: potential biomarkers |
| Q34542848 | Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial |
| Q91933143 | Functional DNA methylation signatures for autism spectrum disorder genomic risk loci: 16p11.2 deletions and CHD8 variants |
| Q57954149 | GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015 |
| Q30410996 | Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome |
| Q26741618 | Genetic Syndromes, Maternal Diseases and Antenatal Factors Associated with Autism Spectrum Disorders (ASD) |
| Q35991106 | Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study. |
| Q47093226 | High resolution metabolomic analysis of ASD human brain uncovers novel biomarkers of disease |
| Q33470697 | Hyperbaric oxygen therapy for children with autism spectrum disorder |
| Q27499262 | Hyperbaric oxygen treatment in autism spectrum disorders |
| Q90573516 | IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin |
| Q26744037 | Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes |
| Q41982904 | Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders |
| Q55091656 | Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. |
| Q53427696 | Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder. |
| Q42286349 | Increased Serum Levels of Tumor Necrosis Factor-Alpha, Resistin, and Visfatin in the Children with Autism Spectrum Disorders: A Case-Control Study. |
| Q35061232 | Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines |
| Q38624639 | Individuals with autism have higher 8-Iso-PGF2α levels than controls, but no correlation with quantitative assay of Paraoxonase 1 serum levels |
| Q90400270 | Inheritance of HLA-Cw7 Associated With Autism Spectrum Disorder (ASD) |
| Q42603766 | Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats |
| Q58790871 | Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism |
| Q87273189 | Introduction |
| Q35659845 | Investigation of Gene Regulatory Networks Associated with Autism Spectrum Disorder Based on MiRNA Expression in China |
| Q47226225 | Is High Folic Acid Intake a Risk Factor for Autism?-A Review |
| Q41918402 | Lipid mediators in plasma of autism spectrum disorders |
| Q92177636 | Mast Cells, Stress, Fear and Autism Spectrum Disorder |
| Q36898075 | Mean serum-level of common organic pollutants is predictive of behavioral severity in children with autism spectrum disorders |
| Q38273909 | Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder |
| Q36764473 | Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study |
| Q38202986 | Metabolic pathology of autism in relation to redox metabolism |
| Q89184197 | Metabolism-Associated Markers and Childhood Autism Rating Scales (CARS) as a Measure of Autism Severity |
| Q28544817 | Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children |
| Q64248477 | Mitochondrial Dysfunction Is Inducible in Lymphoblastoid Cell Lines From Children With Autism and May Involve the TORC1 Pathway |
| Q37648905 | Mitochondrial abnormalities in temporal lobe of autistic brain |
| Q39173130 | Mitochondrial and redox abnormalities in autism lymphoblastoid cells: a sibling control study |
| Q42701655 | Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: A blinded case-control study |
| Q26824822 | Mitochondrial function and dysfunction: an update |
| Q42062971 | Modeling autism: a systems biology approach |
| Q47194149 | Modulation of Immunological Pathways in Autistic and Neurotypical Lymphoblastoid Cell Lines by the Enteric Microbiome Metabolite Propionic Acid |
| Q47316938 | Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism |
| Q35585726 | Modulation of the genome and epigenome of individuals susceptible to autism by environmental risk factors |
| Q48284566 | Monoamine oxidase-A and B activities in the cerebellum and frontal cortex of children and young adults with autism. |
| Q24630108 | My experience learning about autism |
| Q26744759 | Neuropathological Mechanisms of Seizures in Autism Spectrum Disorder |
| Q89477351 | Neuropsychopathology of Autism Spectrum Disorder: Complex Interplay of Genetic, Epigenetic, and Environmental Factors |
| Q47730175 | Novel biomarkers of metabolic dysfunction is autism spectrum disorder: potential for biological diagnostic markers. |
| Q64252273 | Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder |
| Q36050758 | Nutritional and Metabolic Biomarkers in Autism Spectrum Disorders: An Exploratory Study |
| Q47885943 | Obesity and associated factors in youth with an autism spectrum disorder. |
| Q37068763 | On the application of quantitative EEG for characterizing autistic brain: a systematic review |
| Q33860884 | Oxidative Stress Challenge Uncovers Trichloroacetaldehyde Hydrate-Induced Mitoplasticity in Autistic and Control Lymphoblastoid Cell Lines. |
| Q34805397 | Oxidative Stress and Erythrocyte Membrane Alterations in Children with Autism: Correlation with Clinical Features |
| Q89565424 | Oxidative Stress in Autism Spectrum Disorder |
| Q59805997 | Oxidative Stress, Maternal Diabetes, and Autism Spectrum Disorders |
| Q37453274 | Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort |
| Q33575000 | Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines |
| Q97526102 | Perinatal Opioid Exposure Primes the Peripheral Immune System Toward Hyperreactivity |
| Q38977281 | Pharmaceuticals and Stem Cells in Autism Spectrum Disorders: Wishful Thinking? |
| Q44425076 | Pomegranate (Punica granatum) peel extract provides protection against mercuric chloride-induced oxidative stress in Wistar strain rats |
| Q26866073 | Potential Role of Selenoenzymes and Antioxidant Metabolism in relation to Autism Etiology and Pathology |
| Q34431317 | Potential therapeutic use of the ketogenic diet in autism spectrum disorders |
| Q35086246 | Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner |
| Q37623106 | Predicting Autism Spectrum Disorder Using Blood-based Gene Expression Signatures and Machine Learning |
| Q59795533 | Prenatal Progestin Exposure Is Associated With Autism Spectrum Disorders |
| Q99608528 | Prenatal air pollution influences neurodevelopment and behavior in autism spectrum disorder by modulating mitochondrial physiology |
| Q50301735 | Prenatal and Perinatal Factors Related to Autism, IQ, and Adaptive Functioning |
| Q36168459 | Prenatal and Postnatal Epigenetic Programming: Implications for GI, Immune, and Neuronal Function in Autism |
| Q34343570 | Prenatal and perinatal analgesic exposure and autism: an ecological link |
| Q28078384 | Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment |
| Q36922396 | Protective and therapeutic potency of N-acetyl-cysteine on propionic acid-induced biochemical autistic features in rats |
| Q37596896 | Protein signatures of oxidative stress response in a patient specific cell line model for autism |
| Q24282598 | Publication bias: what are the challenges and can they be overcome? |
| Q37284060 | Purinergic signaling and energy homeostasis in psychiatric disorders |
| Q27014070 | ROS and brain diseases: the good, the bad, and the ugly |
| Q46158085 | Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder |
| Q47778501 | Recent Research Progress in Autism Spectrum Disorder |
| Q36956659 | Redox metabolism abnormalities in autistic children associated with mitochondrial disease |
| Q28389692 | Reduced sulfate plasma concentrations in the BTBR T+tf/J mouse model of autism |
| Q58803233 | Resveratrol ameliorates prenatal progestin exposure-induced autism-like behavior through ERβ activation |
| Q91867592 | Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism |
| Q47914021 | Review of reviews on exposures to synthetic organic chemicals and children's neurodevelopment: Methodological and interpretation challenges |
| Q40128301 | Role of SIRT1/PGC-1α in mitochondrial oxidative stress in autistic spectrum disorder |
| Q55279769 | Role of maternal health and infant inflammation in nutritional and neurodevelopmental outcomes of two-year-old Bangladeshi children. |
| Q97554029 | Scrutinizing the molecular, biochemical, and cytogenetic attributes in subjects with Rett syndrome (RTT) and their mothers |
| Q38619694 | Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis |
| Q41501738 | Serum levels of soluble platelet endothelial cell adhesion molecule-1 and vascular cell adhesion molecule-1 are decreased in subjects with autism spectrum disorder. |
| Q34826822 | Sex/gender differences and autism: setting the scene for future research |
| Q37106022 | Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders |
| Q34519678 | Shorter telomere length in peripheral blood leukocytes is associated with childhood autism |
| Q37543326 | Sleep Disorder, Gastrointestinal Problems and Behaviour Problems Seen in Autism Spectrum Disorder Children and Yoga as Therapy: A Descriptive Review |
| Q30823493 | Sleep, plasticity and the pathophysiology of neurodevelopmental disorders: the potential roles of protein synthesis and other cellular processes |
| Q53411833 | Study of the Effect of Bisphenol A on Oxidative Stress in Children with Autism Spectrum Disorders. |
| Q33853973 | Targeted placental deletion of OGT recapitulates the prenatal stress phenotype including hypothalamic mitochondrial dysfunction |
| Q33613009 | The Gut Microbiota and Autism Spectrum Disorders |
| Q37626366 | The Major Histocompatibility Complex (MHC) in Schizophrenia: A Review |
| Q41913940 | The Pivotal Role of Aldehyde Toxicity in Autism Spectrum Disorder: The Therapeutic Potential of Micronutrient Supplementation |
| Q47551499 | The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder |
| Q92252661 | The gut microbiome in psychiatry: A primer for clinicians |
| Q39670262 | The gut: a triggering place for autism - possibilities and challenges |
| Q35246024 | The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders |
| Q38162501 | The need for a comprehensive molecular characterization of autism spectrum disorders |
| Q40892251 | The plausibility of maternal toxicant exposure and nutritional status as contributing factors to the risk of autism spectrum disorders |
| Q28597177 | The potential role of nitrous oxide in the etiology of autism spectrum disorder |
| Q35813000 | The second brain in autism spectrum disorder: could connexin 43 expressed in enteric glial cells play a role? |
| Q34658005 | The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders |
| Q33814205 | Treatments for biomedical abnormalities associated with autism spectrum disorder. |
| Q92131861 | Unified Behavioral Scoring for Preclinical Models |
| Q30534798 | Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder |
| Q92941286 | Urinary Markers of Oxidative Stress in Children with Autism Spectrum Disorder (ASD) |
| Q64230437 | Variations in Mitochondrial Respiration Differ in IL-1ß/IL-10 Ratio Based Subgroups in Autism Spectrum Disorders |
| Q37055829 | Vitamin D in Children's Health |
| Q47106959 | Warburg effect hypothesis in autism Spectrum disorders |
| Q49773786 | Oxygénothérapie hyperbare pour les enfants atteints du trouble du spectre autistique. |
Search more.